Evaxion Biotech’s Earnings Call Highlights Strategic Growth
TipRanks (Fri, 7-Nov 8:03 PM ET)
Evaxion Unveils New Immune Data for AI-Designed Cancer Vaccine
TipRanks (Fri, 7-Nov 5:52 PM ET)
Globe Newswire (Fri, 7-Nov 5:10 PM ET)
Lake Street Keeps Their Buy Rating on Evaxion Biotech (EVAX)
TipRanks (Fri, 7-Nov 11:16 AM ET)
Evaxion Biotech Reports Strong Q3 2025 Results
TipRanks (Fri, 7-Nov 12:45 AM ET)
Evaxion Biotech Announces New CEO and Promising Vaccine Developments
TipRanks (Thu, 6-Nov 8:14 AM ET)
Evaxion Biotech ADS GAAP EPS of $0.01 beats by $0.02, revenue of $7.49M beats by $4.99M
Seeking Alpha News (Thu, 6-Nov 7:37 AM ET)
Evaxion announces business update and third quarter 2025 financial results
Globe Newswire (Thu, 6-Nov 7:30 AM ET)
Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
Globe Newswire (Mon, 3-Nov 9:00 AM ET)
Globe Newswire (Fri, 31-Oct 9:05 AM ET)
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
Evaxion A/S - American Depositary Share trades on the NASDAQ stock market under the symbol EVAX.
As of November 7, 2025, EVAX stock price climbed to $6.38 with 156,698 million shares trading.
EVAX has a beta of 0.95, meaning it tends to be less sensitive to market movements. EVAX has a correlation of 0.00 to the broad based SPY ETF.
EVAX has a market cap of $50.55 million. This is considered a Micro Cap stock.
Last quarter Evaxion A/S - American Depositary Share reported $7 million in Revenue and $.01 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.22.
In the last 3 years, EVAX traded as high as $610.00 and as low as $1.20.
EVAX has underperformed the market in the last year with a return of -90.3%, while SPY returned +13.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in EVAX shares. However, EVAX has outperformed the market in the last 3 month and 2 week periods, returning +117.7% and +8.3%, while SPY returned +6.4% and -0.9%, respectively. This indicates EVAX has been having a stronger performance recently.
EVAX support price is $5.50 and resistance is $7.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVAX shares will trade within this expected range on the day.